Group 1 - Tsinghua Dongbao (600867.SH) reported its Q3 2025 results, with 9 institutional investors holding a total of 928 million shares, representing 47.39% of the total share capital [1] - The institutional holding ratio increased by 0.77 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, namely the Innovative Medicine fund, increased its holdings slightly, while two funds, including the China Securities National Biomedicine Index A and Southern CSI 500 ETF, reduced their holdings by 0.17% [2] - A total of 249 public funds did not disclose their holdings this period, including Tianhong National Biomedicine ETF and Guotai CSI Biomedicine ETF [2] Group 3 - MACD golden cross signals have formed, indicating a positive trend for certain stocks [3]

Group 1 - Tianhong Fund announced the resignation of Liu Rongkui as Chief Information Officer due to work reasons, with Chi Zhe taking over the role [1][2] - Chi Zhe has over 20 years of experience in the financial industry, previously holding positions at well-known institutions such as Shenyin Wanguo, Accenture, and Taikang Asset Management [2] - The management changes at Tianhong Fund, including at least four adjustments since Gao Yang became General Manager in December 2023, may indicate a potential shift in the company's operational direction [2] Group 2 - Tianhong Fund's management scale has decreased to 1.2 trillion yuan as of mid-2025, dropping to the fifth position in industry rankings, with the scale of its Yu'ebao money market fund further shrinking to less than 800 billion yuan [3] - The biopharmaceutical sector, once promising, has become a "typical loss" in active equity products, with the Tianhong Guozheng Biopharmaceutical ETF down 54.41% since its launch, resulting in a loss of over 5,400 yuan for every 10,000 yuan invested [4] - Despite multiple funds experiencing losses, significant dividends have been distributed to executives, leading to a decline in investor trust as the company faces ongoing pressure from shrinking scale and performance [4]

Group 1 - Wante Bio (603392.SH) released its 2024 annual report on April 12, 2025, indicating that as of April 11, 2025, 219 institutional investors disclosed holding A-shares of Wante Bio, totaling 778 million shares, which accounts for 61.50% of the total share capital [1] - The top ten institutional investors include companies such as Yangshengtang Co., Ltd., Hong Kong Central Clearing Limited, and various ETFs, with the top ten collectively holding 60.17% of the shares, a decrease of 0.29 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 22 funds increased their holdings compared to the previous period, with a total increase of 0.16%, including funds like Innovation Drug and Tianhong National Medicine ETF [2] - Conversely, 6 public funds reduced their holdings, with a total decrease of 0.11%, including funds such as Huatai-PB CSI 300 ETF and Morgan CSI Innovation Drug Industry ETF [2] - A total of 189 new public funds were disclosed this period, including major ETFs like E Fund CSI 300 Medicine ETF and Huaxia CSI 300 ETF [2]